Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 44

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

297

HTML

2183

Figures (1-4)

147

Tables (1-1)

126

Sum=2753

Nov 28, 2005 (publication date) through Apr 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Nov 28, 2005; 11(44): 7001-7006
Published online Nov 28, 2005. doi: 10.3748/wjg.v11.i44.7001

Full Size Figure Download Figure

Figure 2 Patients (ITT analysis) in clinical remission or improved during a 4-mo follow-up period without additional apheresis therapy.

Citation: Kruis W, Dignass A, Steinhagen-Thiessen E, Morgenstern J, Mössner J, Schreiber S, Vecchi M, Malesci A, Reinshagen M, Löfberg R. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol 2005; 11(44): 7001-7006
URL: https://www.wjgnet.com/1007-9327/full/v11/i44/7001.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i44.7001